3 Stocks Driving The Health Services Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 120 points (-0.7%) at 17,956 as of Thursday, June 4, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 740 issues advancing vs. 2,233 declining with 147 unchanged.

The Health Services industry currently sits down 0.2% versus the S&P 500, which is down 0.5%. On the negative front, top decliners within the industry include Opko Health ( OPK), down 10.8%, Agilent Technologies ( A), down 1.6%, Smith & Nephew ( SNN), down 1.5%, Boston Scientific ( BSX), down 1.3% and Stryker Corporation ( SYK), down 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Bio-Reference Laboratories ( BRLI) is one of the companies pushing the Health Services industry higher today. As of noon trading, Bio-Reference Laboratories is up $9.35 (28.4%) to $42.31 on heavy volume. Thus far, 5.0 million shares of Bio-Reference Laboratories exchanged hands as compared to its average daily volume of 173,600 shares. The stock has ranged in price between $42.20-$46.74 after having opened the day at $45.65 as compared to the previous trading day's close of $32.96.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases in the United States. Bio-Reference Laboratories has a market cap of $904.1 million and is part of the health care sector. Shares are up 2.6% year-to-date as of the close of trading on Wednesday. Currently there are no analysts who rate Bio-Reference Laboratories a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Bio-Reference Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Bio-Reference Laboratories Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Mindray Medical International ( MR) is up $2.08 (7.6%) to $29.55 on heavy volume. Thus far, 2.4 million shares of Mindray Medical International exchanged hands as compared to its average daily volume of 621,800 shares. The stock has ranged in price between $28.63-$30.00 after having opened the day at $28.75 as compared to the previous trading day's close of $27.47.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Mindray Medical International Limited develops, manufactures, and markets medical devices worldwide. The company operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems. Mindray Medical International has a market cap of $3.2 billion and is part of the health care sector. Shares are up 4.0% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts who rate Mindray Medical International a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Mindray Medical International as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Mindray Medical International Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Laboratory Corp of America Hldgs ( LH) is up $2.38 (2.0%) to $119.75 on average volume. Thus far, 611,162 shares of Laboratory Corp of America Hldgs exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $116.63-$119.93 after having opened the day at $116.92 as compared to the previous trading day's close of $117.37.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. Laboratory Corp of America Hldgs has a market cap of $11.8 billion and is part of the health care sector. Shares are up 8.8% year-to-date as of the close of trading on Wednesday. Currently there are 14 analysts who rate Laboratory Corp of America Hldgs a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Laboratory Corp of America Hldgs as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Laboratory Corp of America Hldgs Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers